Directly targeting AKT has encountered clinical challenges due to tumor heterogeneity, genetic alterations, limited specificity, and significant side effects, compromising the efficacy and clinical utility of AKT inhibitors [21, 22, 24, 25, 27, 28]. This evidence concerns the gene AKT1 and neoplasm.